Back to Search Start Over

Exon 2: Is it the good police in familial mediterranean fever?

Authors :
Yavuz Pehlivan
M. Cinar
Emel Gönüllü
Dilek Solmaz
Bunyamin Kisacik
Umut Kalyoncu
Müge Aydın Tufan
Fezan Sahin
Sibel Yilmaz Oner
Eren Erken
Cemal Bes
Haner Direskeneli
Veli Yazisiz
Duygu Ersozlu Bozkirli
Ismail Sari
Gozde Yildirim Cetin
Mehmet Sayarlioglu
Levent Kilic
Şule Yaşar Bilge
Timuçin Kaşifoğlu
Fatih Yildiz
Servet Akar
Sedat Yilmaz
Soner Senel
Kenan Aksu
Hakan Emmungil
Şükran Erten
Sema Yilmaz
Çukurova Üniversitesi
Selçuk Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
Yılmaz, Sema
Ege Üniversitesi
Bilge, Sule Yasar
Solmaz, Dilek
Senel, Soner
Emmungil, Hakan
Kilic, Levent
Oner, Sibel Yilmaz
Yidiz, Fatih
Yilmaz, Sedat
Bozkirli, Duygu Ersozlu
Tufan, Muge Aydin
Yilmaz, Sema
Yazisiz, Veli
Pehlivan, Yavuz
Bes, Cemal
Cetin, Gozde Yildirim
Erten, Sukran
Gonullu, Emel
Sahin, Fezan
Akar, Servet
Aksu, Kenan
Kalyoncu, Umut
Direskeneli, Haner
Erken, Eren
Kisacik, Bunyamin
Sayarlioglu, Mehmet
Cinar, Muhammed
Kasifoglu, Timucin
Sari, Ismail
Source :
European Journal of Rheumatology, European Journal of Rheumatology, Vol 6, Iss 1, Pp 34-37 (2019)
Publication Year :
2018
Publisher :
Medical Research and Education Association, 2018.

Abstract

WOS: 000463722100007<br />PubMed ID: 30489254<br />Objective: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease. Most of the identified disease-causing mutations are located on exon 10. As the number of studies about the effect of the exonal location of the mutation and its phenotypic expression is limited, we aimed to investigate whether the exonic location of the Mediterranean fever (MEFV) mutation has an effect on the clinical manifestation in patients with FMF. Methods: Study population was derived from the main FMF registry that included 2246 patients from 15 different rheumatology clinics. We categorized the mutations according to their exon locations and retrieved the clinical and demographic information from the database. Results: Patients having the MEFV mutations on exon 2 or 10 (n: 1526) were divided into three subgroups according to the location of the MEFV mutations: Group 1 (exon 2 mutations), Group 2 (exon 10 mutations), and Group 3 (both exon 2 and exon 10 mutations). Group 2 patients were of a significantly younger age at onset, and erysipel-like erythema, arthritis, amyloidosis, and a family history of FMF were more common in this group. Conclusion: Patients with FMF and exon 10 mutations show more severe clinical symptoms and outcome. Exon 2 mutations tend to have a better outcome.

Details

Language :
English
ISSN :
21484279 and 21479720
Volume :
6
Issue :
1
Database :
OpenAIRE
Journal :
European Journal of Rheumatology
Accession number :
edsair.doi.dedup.....128f656a19135f4328c48682fa865652